AbbVievsBillionToOne

ABBV and BLLN stock compared: price, dividend, valuation and results, from SEC filings.

BLLN

BillionToOne, Inc.

$97.51

Value $4.6B

-7.27%
BLLN's page

AbbVie (ABBV) has a market value of $523B and BillionToOne (BLLN) $4.6B. Over the last year, with dividends, ABBV moved +31.1% and BLLN +8.3%. The P/E is 50.8 for ABBV and 100.3 for BLLN. Dividend yield: ABBV 2.34%, BLLN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$523B

    BLLN$4.6B

    ABBV is 113 times BLLN

  • Revenue, 12 months

    ABBV$66.0B

    BLLN$437M

    ABBV is 151 times BLLN

  • Net income, 12 months

    ABBV$10.3B

    BLLN$49M

    ABBV is 209 times BLLN

  • Operating margin

    ABBV32.2%

    BLLN10.2%

    22.0 points apart

  • ROIC

    ABBV25.7%

    BLLN7.9%

    17.8 points apart

  • P/E

    ABBV50.8

    BLLN100.3

    BLLN is 2.0 times ABBV

  • Dividend yield

    ABBV2.3%

    BLLN0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+31.1%

BLLN+8.4%

100150DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsBLLNWith dividends
1 year since November 14, 2025+31.1%Price +27.3%+8.3%Price +8.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieBLLNBillionToOne

Valuation

ABBVBLLN
Valuation
Price$295.88$97.51
Market value$523B$4.6B
Enterprise value (EV)$593B$4.1B
P/E50.8100.3
P/E, 5-year median57.0–
P/B–8.1
EV/EBIT27.992.6
Free cash flow yield3.6%0.7%

Results and growth

ABBVBLLN
Results and growth
Revenue, 12 months$66.0B$437M
Net income, 12 months$10.3B$49M
Free cash flow, 12 months$18.9B$34M
Earnings per share, 12 months$5.81$0.97
Revenue growth, year on year8.6%100.0%
Revenue growth a year, past+5.9%over 5 years+106.2%over 2 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVBLLN
Margins and returns on capital
Gross margin73.7%71.4%
Operating margin32.2%10.2%
Net margin15.7%11.3%
ROIC25.7%7.9%
ROE–13.4%

Balance sheet

ABBVBLLN
Balance sheet
Cash$10.8B$562M
Total debt$80.9B$140M
Net debt / EBITDA3.2-9.2
Interest cover7.1×1,655.3×

Dividends and buybacks

ABBVBLLN
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or BLLN

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or BillionToOne?

By market value, AbbVie ($523B) is about 113.5 times BillionToOne ($4.6B), at today's prices.

How did ABBV and BLLN stock do over the last 1 years?

Since November 14, 2025, ABBV's price moved +27.3% and BLLN's +8.3%. With dividends: ABBV +31.1% (+31.1% a year), BLLN +8.3% (+8.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or BLLN?

The dividend yield at today's price is 2.34% for AbbVie and none for BillionToOne. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and BLLN?

At today's price, the P/E is 50.8 for ABBV and 100.3 for BLLN. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or BillionToOne?

Over the last twelve months, the net margin was 15.7% for AbbVie and 11.3% for BillionToOne, and the operating margin 32.2% and 10.2%. Revenue was $66.0B and $437M.

Which is the better investment, AbbVie or BillionToOne?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.